Introduction
============

Hashimoto's thyroiditis (HT), which is characterized by the production of autoantibodies against the thyroid gland, is a localized autoimmune disease. HT has been found to have a 55% concordance rate in monozygotic twins.^[@bib1]^ Repplinger *et al.*^[@bib2]^ reported that there is a high prevalence for the increased occurrence of HT in women, which is seven times greater than in men. Different genetic and environmental factors are involved in the pathogenesis of this disease.^[@bib3]^ It is well established that the chronic inflammation that occurs during the course of HT causes a significant increase in the levels of cytokines and other inflammatory mediators, which ultimately leads to the destruction of the thyroid gland.^[@bib4]^ More precisely, the interactions of multiple genes and environmental factors can increase susceptibility to HT and the severity of the disease.^[@bib5]^

Poly(ADP-ribose) polymerase-1 (PARP-1) is thought to be one of the candidate genes responsible for the pathogenesis of inflammatory situations. *PARP-1* is thought to have an important role in the initiation of the DNA repair pathway, although high levels of its activation are also associated with increased apoptosis. Recently, it was shown that the development and progression of inflammatory diseases were impeded in *PARP-1* knockout animal models that used *PARP-1* inhibitors.^[@bib6],[@bib7]^ Results from several studies have shown that the inactivation of PARP-1 protects against endotoxic shock, colitis, lung inflammation and other diseases, such as traumatic brain injury, cerebral and myocardial ischemia, stroke, rheumatoid arthritis and diabetes mellitus-associated heart disease.^[@bib8; @bib9; @bib10; @bib11; @bib12; @bib13; @bib14; @bib15]^ Although, the exact role of *PARP-1* in the inflammatory cascade is not yet known, all of the available studies on *PARP-1* suggest that this gene is a strong candidate and genetic factor for the development of HT.

The *PARP-1* gene (OMIM [173870](http://www.omim.org/entry/173870)), which localizes to chromosome one (1q41-43), has been shown to accommodate allelic polymorphisms that have been linked to susceptibility for various diseases, some of which are inflammatory disorders.^[@bib16]^ In addition, multiple binding sites for transcription factors have been identified in the *PARP-1* gene promoter region; therefore, genetic variants within this region may affect PARP-1 expression.^[@bib17]^ Several variations (C410T (rs2793378), Poly(A)n, C1362T and G1672A (rs7527192)) have been identified in the promoter region, and there are several studies that have investigated the relationship between these promoter polymorphisms and the pathogenesis of many diseases.^[@bib16],[@bib17]^ In addition, the active-site polymorphism T2444C (rs1136410) (also known as Val762Ala), which causes a T to C, Val to Ala change in exon 17, was identified by Cottet *et al.*^[@bib18]^ According to Wang and colleagues, the T2444C polymorphism reduces the enzymatic activity of *PARP-1* by \~40%.^[@bib16],[@bib19],[@bib20]^

In this study, we questioned whether two promoter polymorphisms (rs2793378 and rs7527192) and an active-site polymorphism (rs1136410) in the *PARP-1* gene could predispose individuals to HT disease in a female Turkish population.

Patients and methods
====================

Study subjects
--------------

One hundred and forty-one women who were diagnosed with HT in the Endocrine and Metabolic Diseases outpatient clinic at Cerrahpasa Medical School, Istanbul University, were included in this study. The control group consisted of one hundred and fifty healthy women with a similar mean age. The exclusion criteria for participation in the study included pregnancy, smoking, use of alcohol or prescription drugs and having an autoimmune disease that might affect the results of the study.

Although Turks are ethnically heterogeneous, all of the cases and controls were carefully chosen from the European side of Istanbul to ensure that all of the individuals were of Turkish origin. All of the study subjects were unrelated and provided signed informed consent prior to the sample and data collection. The study protocol was approved by the Institutional Ethical Committee of Cerrahpasa Medical School, Istanbul University.

Genotyping of the PARP-1 polymorphisms
--------------------------------------

The genomic DNA from the study subjects was isolated using an ethanol precipitation method. The concentration and purity of the DNA was measured on a NanoDrop Spectrophotometers (NanoDrop Technologies Inc., Wilmington, DE, USA) and determined using a 260/280 nm optic density ratio. The *PARP-1* C410T and G1672A genotypes were determined using a polymerase chain reaction (PCR) based restriction fragment length polymorphism (RFLP) method. The primers used to amplify the polymorphic sites were F: 5′-TCCAGTGGCACTATCAT-3′ and R: 5′-GTTGTGAGACATAGGCCGAATC-3′ for rs2793378, and F: 5′-GCGAGACCCTGTCCCTAA-3′ and R: 5′-TCCCCCTTTTATTTTTGAGACTG-3′ for rs7527192.^[@bib16]^

The amplification products yielded a 298-base pair (bp) fragment for rs2793378 and a 187 bp fragment for rs7527192. Ten microliters of the amplification product of rs2793378 were digested with one unit of *Hpy31 (Dde I)* (New England Biolabs, Beverly, MA, USA), incubated for 12 h at 37 °C, and subjected to electrophoresis for 30 min at 120 V on a 3% agarose gel. The homozygosity of the common allele (represented by the CC genotype) was denoted via 145 and 109 bp bands, while the homozygosity of the variant allele (represented by the TT genotype) was represented by 127 and 109 bp bands. Ten microliters of the amplification product of rs7527192 were digested with one unit of *Bsh1236I (BstUI)* (MBI, Fermentas, Vilnius, Lithuania), incubated for 12 h at 37 °C, and separated on a 3% agarose gel. The homozygosity of the common allele (represented by the GG genotype) was denoted via 152 and 35 bp bands, while the homozygosity of the variant allele (represented by the AA genotype) was represented by a single 187 bp band, as this polymorphism destroys a restriction site for *Bsh1236I*.^[@bib20]^

For rs1136410, the PCR conditions were set at 95 °C for 4 min for the denaturation, followed by 35 cycles of 94 °C for 30 s, 62 °C for 45 s and 72 °C for 45 s for the annealing step, followed by a final extension at 72 °C for 10 min. The primers that were used are as follows: forward primer 5′-TGAGGAAGGCCTGACCCTGT-3′ and reverse primer 5′-TGACCAGCAGGAGGGTTTGC-3′. The sequential alterations for rs1136410 were determined using bidirectional sequencing. The amplicon sequences were evaluated using CLC workbench 3.6.1 (Denmark).

Haplotype analysis
------------------

Haplotypes were generated from the genotype data. The linkage disequilibrium (LD) and haplotype analyses were performed using Haploview 4.2, which uses the expectation maximization (EM) algorithm.

Data processing and analysis
----------------------------

The statistical analyses were performed using the Statistical Package for Social Sciences Statistical Software release 18 (SPSS Windows Version 18, SPSS, Inc., Chicago, IL, USA). The Hardy--Weinberg equilibrium (HWE) was determined in order to identify the compatibility between the patient and control groups using *χ*^2^-tests. The relationships between different parameters were evaluated using Spearman's correlation analysis. The comparison of the frequencies and ratios between the groups was evaluated using *χ*^2^- and Fisher's exact tests. The quantitative data containing normally distributed parameters between the groups were evaluated using Student's t-test, while Mann--Whitney *U-*test was used for the remaining samples. The associations between the rs2793378, rs7527192 and rs1136410 genotypes and HT were analyzed by calculating the odds ratios (ORs) and their 95% confidence intervals (95% CIs) using the *χ*^2^-test, accepting the homozygous common genotypes as the reference category for each polymorphism. As this study was based on a small sample size and there were several multiple comparisons, the results could have arisen from a type I error. The confidence in the results will generally be weaker if it is conducted as part of a multiple comparison analysis, rather than a single comparison analysis. Therefore, to address the multiple comparison problem, a Bonferroni correction was applied to the comparisons. The Bonferroni correction is a conservative method that is free of independency and distribution assumptions. The Bonferroni correction set the significance level at α (alpha)/*n* (number of comparisons). The specific multiple comparisons that were used for each Bonferroni-corrected *P* value are stated below each table.

Results
=======

Study population
----------------

A total of 141 Hashimoto thyroiditis patients, aged between 39 and 55 years old (mean, 48.9 year), and 150 control subjects, aged between 37 and 54 years old (mean, 46.6 year), were recruited in this study. There was no significant difference between the ages of the cases and the controls.

The mean levels of thyroid stimulating hormone (TSH), AntiTPO and AntiTG antibody in the HT patients in this study were found to be 8.3±6.8  μIU/ml, 806.7±447.3 IU/ml and 382.7±207.4 IU/ml, respectively. The TSH, AntiTg and AntiTPO antibody levels of the control subjects were 2.8±1.2 μIU/ml, 65.4±59.7  IU/ml and 27±15.8 IU/ml, respectively. The levels of the TSH, AntiTPO and AntiTG antibodies of the HT patients were statistically higher than the control group, as was expected (*P*=0.0305, 0.0296, 0.0242, respectively).

The 141 HT patients and 150 control subjects were tested for rs2793378, rs7527192 and rs1136410. There were no statistically significant differences between the patients and controls in terms of their mean age (41.1±11.7 years, *P*=0.352), gender (all female, *P*=0.881) and ethnicity (Turkish), indicating that the frequency matching between the groups was adequate.

Distribution of the PARP-1 SNPs in HT
-------------------------------------

The distribution of the rs2793378, rs7527192 and rs1136410 genotypes in the control group were within HWE. The distribution of the genotypes and the allele frequencies of all of the studied polymorphisms are shown in [Table 1](#tbl1){ref-type="table"}.

We found a significant association between *PARP-1* rs1136410 and rs7527192 and HT. The frequency of the heterozygous TC genotype of rs1136410 was significantly greater in the controls compared to the patients (OR: 2.504, 95% CI: 1.48--4.23, *P*=0.001). Moreover, the frequency of the C allele of rs1136410 was found to be statistically higher in the healthy group (OR: 1.632, 95% CI: 1.1--2.403, *P*=0.013), and rs1136410 maintained its significance following Bonferroni correction. The frequency of the heterozygous GA genotype of rs7527192 was significantly higher in the controls (OR: 1.633, 95% CI: 1.017--2.623, *P*=0.042) than in the patients. Additionally, the frequency of the A allele of rs7527192 was found to be statistically higher in the healthy group (OR: 1.492, 95% CI: 1.039--2.142, *P*=0.03); although, neither the GA genotype nor the A allele of rs7527192 maintained significance following Bonferroni correction. In addition, the C allele of rs1136410 showed no significance following Bonferroni correction, and *PARP-1* rs2793378 showed no protective or risk effect in HT disease. All of the results are shown in [Table 1](#tbl1){ref-type="table"}.

Haplotype analysis of the PARP-1 SNPs
-------------------------------------

We also investigated whether the three polymorphisms were in linkage disequilibrium, and any common haplotypes associated with diseases and rare haplotypes (with a frequency \<5%) were excluded from the association analyses. The most common haplotypes of the three polymorphisms, calculated by Haploview 4.2, are summarized in [Table 2](#tbl2){ref-type="table"}.

The haplotypes were generated using the three *PARP-1* intragenic SNPs (rs2793378, rs7527192 and rs1136410) among the HT cases and controls, and six different haplotypes were generated (with a frequency \>5%).

The prevalence of the CGC haplotype was significantly higher in the controls (ratio of the cases to the controls: 0.061:0.146, *P*=0.0252, *x*^*2*^=5.01), as shown in [Table 2](#tbl2){ref-type="table"}. The first marker of the CGC haplotype, the C allele, is wild type for rs2793378. The second marker of the CGC haplotype, the G allele, is wild type for rs7527192. The third marker, the C allele, is mutant for rs1136410. The difference was based on the third marker, the C allele of rs1136410, which serves as a protective factor. However, because this study was based on a small sample size, we applied a Bonferroni correction to decrease the type I error. Following Bonferroni correction, the haplotype analysis did not show any significance. Furthermore, two of the SNPs in *PARP-1* (rs1136410 and rs7527192) were in strong LD ([Figure 1](#fig1){ref-type="fig"}).

Combined genotype analysis of the PARP-1 SNPs
---------------------------------------------

[Tables 3](#tbl3){ref-type="table"}, [4](#tbl4){ref-type="table"}, [5](#tbl5){ref-type="table"} summarize the association studies among the combined genotypes of the three SNPs and the overall risk for HT. The *PARP-1* rs2793378 and rs7527192 SNPs showed statistical significance among the combined genotypes in the HT patients and controls. The combined CC/GA, CT/GG and TT/GA genotype frequencies were significantly higher in the control group versus the HT group when compared with the combined CC/GG genotype (OR: 2.956, 95% CI: 1.114--7.840, *P*=0.027; OR: 2.66, 95% CI: 1.13--6.259, *P*=0.023; OR: 4.644, 95% CI: 1.455--14.822, *P*=0.007, respectively). Following Bonferroni correction, only the combined TT/GA genotype remained significant and was found to be a significant protective factor against HT disease (*P*=0.007), as shown in [Table 3](#tbl3){ref-type="table"}.

Aside from the abovementioned results, there were no other significant differences between the multiple comparisons of rs7527192-rs1136410, and rs2793378-rs1136410 in the HT patients and control groups ([Tables 4](#tbl4){ref-type="table"} and [5](#tbl5){ref-type="table"}).

Discussion
==========

Based on genome-wide association studies (GWAS) of thyroid disorders, it is clear that genetic factors are thought to be considerable determinants of thyroid function and autoimmunity. Recently, an intronic variant of *VAV3* (vav 3 guanine nucleotide exchange factor, rs12126655) was found to be associated with TSH concentrations, and another variant (rs2071403) located 75 bp proximal to the translation start site of *TPO* was found to be significantly associated with plasma anti-TPO antibody positivity. Another intronic variant of *HLA-DPB2* (rs733208) was associated with anti-TPO antibody positivity as well.^[@bib21]^ Eriksson *et al.*^[@bib22]^ showed evidence of an association between hypothyroidism and autoimmune thyroid diseases with SNPs in the HLA class I and II regions (rs2517532 and rs2516049, respectively), and near the *CAPZB* (capping protein (actin filament) muscle Z-line, beta, rs12091047), *PDE8B* (phosphodiesterase 8B, rs4704397) and *CTLA-4* (toxic T lymphocyte antigen-4, rs231779) genes. Based on candidate gene studies, it is known that *CTLA-4* is widely associated with many other autoimmune diseases, including autoimmune hypothyroidism.

In addition, variants near *FOXE1*, a thyroid transcription factor, were identified as genetic risk factors for primary hypothyroidism.^[@bib23]^ In a GWAS of *FoxE1*, it was suggested that *FoxE1* and *PARP-1* participate in the human NIS repressor complex, which is a trans-active transcriptional repressor found in thyroid cancer cells that contains PARP-1 and functions via its poly(ADP-ribosyl)ation activity.^[@bib24],[@bib25]^ Therefore, *PARP-1* is a strong and suitable candidate gene for identifying associations between genetic factors in thyroid autoimmunity.

Several studies strongly support that *PARP-1* plays a considerable role in autoimmune inflammatory disorders.^[@bib17],[@bib26],[@bib27]^ *PARP-1* inhibitors or *PARP-1* deletions are being used in many therapeutic approaches that are based on blocking tissue or systemic inflammation.^[@bib28],[@bib29]^ Recently, alternative pathways have been suggested involving the capability of *PARP-1* to regulate the transcription of inflammation-linked genes. Several recent publications indicate that the nuclear protein PARP-1 regulates the transcription and synthesis of inflammatory mediators.^[@bib30]^ In addition, the relationship between PARP-1 activity and inflammation has been widely investigated, and the link with inflammation was firmly established via the pharmacological inhibition of PARP-1 activity, which allowed the attenuation of the inflammatory response.^[@bib6],[@bib30]^ The inhibition of *PARP-1* activity is protective in a wide range of inflammatory conditions, such as cardiovascular disease, diabetes, rheumatoid arthritis and stroke.^[@bib13],[@bib31]^ Therefore, the *PARP-1* gene may be a strong candidate based on the observations made in knockout mice, and it provides promising therapeutic approaches to inflammatory diseases using *PARP-1* inhibitors.

Alternatively, PARP-1 protein concentration is controlled by the direct regulation of promoter activity. Therefore, polymorphisms within the promoter region may also affect *PARP-1* activity. Multiple transcription sites, as well as 3 sets of CCAAT/TATA boxes, have been identified in the promoter region, which provide a binding site for YY1 transcription factors.^[@bib20]^ In addition, four sequence variations have been identified in this region: rs2793378, Pol(A)n, C1362T and rs7527192.^[@bib16],[@bib20]^ According to Infante *et al.,*^[@bib32]^ the C410T polymorphism that is found in the heterozygous state increased the risk for Parkinson's disease, while rs7527192 heterozygosity significantly delayed the onset of the disease. In this study, we did not find any significance in regards to rs2793378.

Recently, rs2793378, rs7527192, and rs1136410 have been investigated in many inflammatory autoimmune diseases, including RA,^[@bib16]^ AR,^[@bib33]^ asthma,^[@bib34]^ nephritis and arthritis in SLE patients^[@bib35]^ and Alzheimer\'s disease,^[@bib36],[@bib37]^ as described above. In our study, the heterozygous GA genotype of *PARP-1* rs7527192 was found to have a protective effect on HT disease in the Turkish population. This is comparable to the results of Infante *et al.*, which showed that certain promoter variations (rs2793378 and rs7527192) are associated with protection against Parkinson's disease.^[@bib24]^ We also previously determined that the heterozygous genotype of rs7527192 was significantly associated with susceptibility to allergic rhinitis (AR) in the Turkish population. Moreover, in this study, according to the multiple comparisons of the combined genotypes of rs2793378--rs7527192, the frequency of the TT/GA combined genotype was significantly higher in the controls versus the HT group when compared with CC/GG combined genotype. Following Bonferroni correction, only the TT/GA genotype continued to show significance as a protective factor. When the mutant form of rs2793378 and the heterozygous form of rs7527192 were combined, a significant protective effect was observed in the HT patients.

The *PARP-1* promoter haplotypes have also been shown to be related to susceptibility to some chronic inflammatory diseases, such as AR, RA and celiac disease.^[@bib16],[@bib33],[@bib38]^ The protective effect of a haplotype of the *PARP-1* gene polymorphisms for Alzheimer\'s disease was also detected.^[@bib37]^ The rs2793378, rs7527192 and rs1136410 haplotypes were not associated with an increased risk for AR.^[@bib33]^ According to Pascual *et al.*,^[@bib16]^ *PARP-1* haplotypes (−410, −1327, CA microsatellite repeat) play a role in susceptibility to RA in the Spanish population, whereas the rs7527192 variant did not appear to be part of this haplotype. Although the CGC haplotype was found to have a protective effect based on the C (Ala) allele of rs1136410, it did not survive Bonferroni correction.

rs1136410 is present in approximately 5--33% of the general population.^[@bib19]^ We previously reported that the T (Val) allele of rs1136410 is associated with an increased risk for asthma.^[@bib34]^ Furthermore, rs1136410 was significantly associated with coronary artery disease, which is also an inflammatory process.^[@bib39]^ Hur *et al.*^[@bib35]^ demonstrated that the nonsynonymous variant +40329T→C(V762A) was also significantly associated with an increased risk for arthritis in Korean SLE patients. However, according to Onaran *et al*.,^[@bib40]^ rs1136410 was not associated with a risk for rheumatoid arthritis. The Val762 variants of *PARP-1* rs1136410 have also been found to increase the risk of diabetic polyneuropathy in Russian type 1 diabetic patients.^[@bib41]^ Additionally, we found that the heterozygous TC (Val/Ala) genotype of rs1136410 still had a protective effect on susceptibility to HT in the Turkish population even following Bonferroni correction.

PARP-1 and nuclear factor kappa B (NF-κB) have both been suggested to play a considerable role in inflammatory diseases. It has been shown that *PARP-1* can act as a coactivator of NF-κB in terms of inflammatory processes in the cell.^[@bib42]^ These findings provided us with new insights into the pathogenesis of different inflammatory disorders, such as HT. We previously reported that the frequency of the deletion allele of *NF-κB1* rs28362491 that accompanies high interleukin-6 (IL-6) levels was significant in an HT patient group.^[@bib43]^ This study is a follow-up to our previous research.

Moreover, it should be kept in mind that the small sample size, which may have influenced the statistical power of our analyses, may be considered to be a limitation of this study. Although a study with low statistical power has a reduced chance of detecting a true effect, case--control studies with small sample sizes are still widely used, and they can be used to assess previously identified candidate regions under selection and more precisely determine the selection targets. Nonetheless, a larger sample size or replication study will provide reassurance for further studies.

We carried out single and combined genotype and haplotype analyses to evaluate the SNPs rs2793378, rs7527192 and rs1136410 in a population-based case--control study. To the best of our knowledge, there are no published studies exploring the associations between these *PARP-1* variants and HT disease. We found that the heterozygous genotype of rs1136410 had a significantly decreased risk for HT disease in a group of women from the Turkish population. Molecular heterosis may be present in 50% of all of the gene associations,^[@bib44]^ and it has also been reported for variations in the *PARP-1* gene.^[@bib32],[@bib34]^ The biological meaning of the \'protective\' effect of the heterozygous genotype of rs1136410 toward HT cannot be easily explained by the existing observations regarding the *PARP-1* SNPs. However, it has been demonstrated that the modulation of cytokine production by various stimulators is more strongly affected by the heterozygous variants of several SNPs in various genes than by the homozygous variant. For example, the heterozygous genotypes of four SNPs (rs7527192, rs2793378, rs28362491 and rs696) were recently found to be related to elevated IL-6, IL-1β and tumor necrosis factor alpha (TNF-α) cytokine production in Graves' disease in a Turkish population.^[@bib45]^ In addition, the 4257GA heterozygous genotype was found to be associated with higher IL-13 levels in asthmatics.^[@bib46]^ A relationship between the heterozygous -137 G/C genotype in the IL-18 gene with elevated IL-18 serum levels and bladder cancer risk was detected in a North Indian population.^[@bib47]^ Moreover, the T cells from heterozygous TC-carrier rheumatoid arthritis patients produced higher TNF-α, IL-17, and interferon-γ when compared with patients carrying the non-TC haplotype.^[@bib48]^ All of these studies show meaningful associations between the heterozygous genotype and increasing cytokine production.

PARP-1 is required for the activation of several transcription factors via the inflammation of several mediators. It has been speculated that a different PARP-1 binding and activation mechanism because of the heterozygous genotype of rs1136410 may affect the expression of the genes involved in the inflammatory response, perhaps via an altered inflammatory pathway. Therefore, this polymorphism may confer a protective effect against HT. However, this hypothesis still requires further investigation.

In summary, it is possible that the interactions of variants of the *PARP-1* gene have key roles in organizing the various changes that occur during the inflammatory response in HT disease. However, replication studies or additional functional studies with a larger sample size are required to confirm the putative protective role of these *PARP-1* gene variants. More precisely, larger trials and replication studies that include different ethnic groups are highly recommended to properly define the relationship between the *PARP-1* polymorphisms (especially rs1136410 TC) and the development of HT, as well as the prognosis of the disease.
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###### Distribution of three SNPs in *PARP-1* gene in Hashimoto thyroiditis

  *Genotype/allele*                           *Cases,* n *(%)*   *Controls,* n *(%)*  *OR (95% CI)*          P*-value*
  ------------------------------------------ ------------------ --------------------- ---------------------- -----------
  rs1136410                                         141                  150                                 
   TT (Val/Val)[a](#t1-fn1){ref-type="fn"}        98 (70)              77 (51)        1                      
   TC (Val/Ala)                                   31 (21)              61 (41)        2.504 (1.48--4.23)     **0.001**
   CC (Ala/Ala)                                    12 (9)              12 (8)         1.273 (0.54--2.99)     0.579
  T (Val) allele frequency                        227 (81)            215 (72)        1                      
  C (Ala) allele frequency                        55 (19)              85 (28)        1.632 (1.1--2.403)     0.013
                                                                                                             
  rs2793378                                         141                  150                                 
   CC                                             62 (44)              60 (40)        1                      
   CT                                             62 (44)              65 (43)        0.92 (0.56--1.52)      0.752
   TT                                             17 (12)              25 (17)        0.66 (0.32--1.34)      0.247
  C allele frequency                              186 (66)            185 (62)        1                      
  T allele frequency                              96 (34)             115 (38)        0.84 (0.47--1.50)      0.556
                                                                                                             
  rs7527192                                         141                  150                                 
   GG                                             75 (53)              60 (40)        1                      
   GA                                             62 (44)              81 (54)        1.633 (1.017--2.623)   0.042
   AA                                              4 (3)                9 (6)         2.813 (0.826--9.581)   0.087
  G allele frequency                              212 (75)            201 (67)        1                      
  A allele frequency                              70 (25)              99 (33)        1.492 (1.039--2.142)   0.03

Abbreviations:

CI, confidence intervals: OR, odds ratios.

The corresponding amino acids of each genotypes of rs1136410 polymorphism were given in parentheses.

The differences resulting from the genotypes were determined by proceeding *χ*^2^-test. *P* value after Bonferroni correction; *P*=5.6×10^−3^ (calculated as 0.05/9). *P* value in bold is still maintained significance after Bonferroni correction.

###### The distribution of PARP-1 haplotypes

  *PARP-1 haplotypes (SNPs)*    *Frequency*   x^2^  P*-value*                           
  ---------------------------- ------------- ------ ----------- ------- ------- ------- --------
  T                                  G         C    0.488       0.521   0.406   2.899   0.0887
  T                                  A         T    0.128       0.132   0.115   0.145   0.7036
  C                                  G         T    0.116       0.121   0.102   0.182   0.6694
  T                                  A         C    0.096       0.091   0.106   0.142   0.7068
  C                                  G         C    0.085       0.061   0.146   5.01    0.0252
  T                                  G         T    0.078       0.065   1.109   1.465   0.2262

Abbreviation: SNP, single-nucleotide polymorphism.

*P* value after Bonferroni correction; *P*=8.3×10^−3^ (calculated as 0.05/6).

###### The distribution of rs2793378- rs7527192 combined genotypes

  *rs2793378- rs7527192 combined genotypes*   *Cases,* n   *Controls,* n        *OR (95% CI)*      P*-value*
  ------------------------------------------- ------------ --------------- ----------------------- -----------
  CC/GG                                       38           15                         1            
  CC/GA                                       12           14               2.956 (1.114--7.840)   0.027
  CT/GG                                       20           21                2.66 (1.13--6.259)    0.023
  CT/GA                                       32           17               1.346 (0.582--3.113)   0.487
  TT/GG                                       6            3                 1.267 (0.28--5.73)    0.711
  TT/GA                                       6            11               4.644 (1.455--14.822)  **0.007**

Abbreviations: CI, confidence intervals; OR, odds ratios.

CC/AA, CT/AA, and TT/AA combined genotypes were excluded in the table as none observed in the subjects or the size was not enough for the statistical analyses. *P* value after Bonferroni correction; *P*=8.3×10^−3^ (calculated as 0.05/6). *P* value in bold is still maintained significance after Bonferroni correction.

###### The distribution of rs7527192--rs1136410 combined genotypes

  *rs7527192*--*rs1136410 combined genotypes*   *Cases* n   *Controls* n       *OR (95% CI)*      P*-value*
  --------------------------------------------- ----------- -------------- ---------------------- -----------
  GG/TT                                         29          10                       1            
  GG/TC                                         13          9               2.008 (0.66--6.111)   0.216
  GG/CC                                         7           2               0.829 (0.147--4.665)  1
  GA/TT                                         30          13              1.257 (0.477--3.314)  0.644
  GA/TC                                         4           2                1.45 (0.23--9.16)    0.65

Abbreviations: CI, confidence intervals; OR, odds ratios.

GA/CC, AA/TC, AA/TT and AA/CC combined genotypes were excluded in the table as none observed in the subjects or the size was not enough for the statistical analyses. *P* value after Bonferroni correction; *P*=0.01 (calculated as 0.05/5).

###### The distribution of rs2793378--rs1136410 combined genotypes

  *rs2793378--rs1136410 Combined Genotypes*   *Cases* n   *Controls* n        *OR (95% CI)*      P*-value*
  ------------------------------------------- ----------- -------------- ----------------------- -----------
  CC/TT                                       34          10                        1            
  CC/TC                                       3           1               1.133 (0.106--12.129)  0.918
  CC/CC                                       3           2               2.267 (0.331--15.509)  0.584
  CT/TT                                       21          8               1.295 (0.441--3.803)   0.637
  CT/TC                                       12          7                 0.58 (0.19--1.78)    0.340
  TT/TT                                       2           2               1.983 (0.616--6.382)   0.247
  TT/TC                                       3           1               1.133 (0.106--12.129)  0.918

Abbreviations: CI, confidence intervals; OR, odds ratios.

CT/CC and TT/CC combined genotypes were excluded in the table as none observed in the subjects or the size was not enough for the statistical analysis. *P* value after Bonferroni correction; *P*=7.1×10^−3^ (calculated as 0.05/7).
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